Mobile Health Intervention to Close the Guidelines-To-Practice Gap in Hypertension Treatment: Protocol for the mGlide Randomized Controlled Trial.
Mobile Health Intervention to Close the Guidelines-To-Practice Gap in Hypertension Treatment: Protocol for the mGlide Randomized Controlled Trial.
复制标题
移动健康干预缩小高血压治疗指南与实践的差距:mGlide随机对照试验方案。
DOI:
10.2196/25424
复制
发表时间:
2021-01-25
影响因子:
1.7
通讯作者:
Everson-Rose SA
中科院分区:
文献类型:
--
作者:
Lakshminarayan K;Murray TA;Westberg SM;Connett J;Overton V;Nyman JA;Culhane-Pera KA;Pergament SL;Drawz P;Vollbrecht E;Xiong T;Everson-Rose SA
Suboptimal treatment of hypertension remains a widespread problem, particularly among minorities and socioeconomically disadvantaged groups. We present a health system–based intervention with diverse patient populations using readily available smartphone technology. This intervention is designed to empower patients and create partnerships between patients and their provider team to promote hypertension control. The mGlide randomized controlled trial is a National Institutes of Health–funded study, evaluating whether a mobile health (mHealth)-based intervention that is an active partnership between interprofessional health care teams and patients results in better hypertension control rates than a state-of-clinical care comparison. We are recruiting 450 participants including stroke survivors and primary care patients with elevated cardiovascular disease risk from diverse health systems. These systems include an acute stroke service (n=100), an academic medical center (n=150), and community medical centers including Federally Qualified Health Centers serving low-income and minority (Latino, Hmong, African American, Somali) patients (n=200). The primary aim tests the clinical effectiveness of the 6-month mHealth intervention versus standard of care. Secondary aims evaluate sustained hypertension control rates at 12 months; describe provider experiences of system usability and satisfaction; examine patient experiences, including medication adherence and medication use self-efficacy, self-rated health and quality of life, and adverse event rates; and complete a cost-effectiveness analysis. To date, we have randomized 107 participants (54 intervention, 53 control). This study will provide evidence for whether a readily available mHealth care model is better than state-of-clinical care for bridging the guideline-to-practice gap in hypertension treatment in health systems serving diverse patient populations. Clinicaltrials.gov NCT03612271; https://clinicaltrials.gov/ct2/show/NCT03612271 DERR1-10.2196/25424
登录
查看更多内容
影响因子:
8.3
作者:
Meschia JF;Bushnell C;Boden-Albala B;Braun LT;Bravata DM;Chaturvedi S;Creager MA;Eckel RH;Elkind MS;Fornage M;Goldstein LB;Greenberg SM;Horvath SE;Iadecola C;Jauch EC;Moore WS;Wilson JA;American Heart Association Stroke Council;Council on Cardiovascular and Stroke Nursing;Council on Clinical Cardiology;Council on Functional Genomics and Translational Biology;Council on Hypertension
通讯作者:
Council on Hypertension
影响因子:
24.3
作者:
Guan, Wei-jie;Liang, Wen-hua;He, Jian-xing
通讯作者:
He, Jian-xing
影响因子:
8.3
作者:
Arima, Hisatomi;Anderson, Craig;Chalmers, John
通讯作者:
Chalmers, John
影响因子:
2.8
作者:
Gee, Marianne E.;Bienek, Asako;Nolan, Robert P.
通讯作者:
Nolan, Robert P.
DOI:
10.1001/jama.2020.6775
发表时间:
2020-01-01
期刊:
JAMA, Journal of the American Medical Association
影响因子:
--
作者:
Richardson, Safiya;Hirsch, Jamie S.;,
通讯作者:
,